Gene therapy takes on hepatitis b: first human trial launches

NCT ID NCT06680232

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a new gene therapy called PBGENE-HBV in 45 adults with chronic hepatitis B who are already on antiviral medication. The goal is to see if the treatment is safe and can help control the virus. Participants must be in good health and have no liver scarring or other infections.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic hepatitis B virus infection hepatitis B virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • ICS ARENSIA Exploratory Medicine SRL

    RECRUITING

    Chisinau, 2025, Moldova

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Massachusetts General Hospital/Harvard University

    RECRUITING

    Boston, Massachusetts, 02114, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • New Zealand Clinical Research

    RECRUITING

    Auckland, 1010, New Zealand

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Queen Mary Hospital, The University of Hong Kong

    RECRUITING

    Hong Kong, Hong Kong, Hong Kong

    Contact Phone: •••-•••-•••• Email: •••••@•••••